NEUPATH HEALTH REPORTS SECOND QUARTER 2026 RESULTS

Article content

As at June 30, 2026, the Company’s net debt was $2.3 million compared to $2.7 million as at June 30, 2025. The Company’s net debt as at June 30, 2026 consisted of $3.5 million of cash and cash equivalents and long-term debt of $5.9 million compared to $3.8 million of cash and cash equivalents and long-term debt of $6.5 million as at June 30, 2025.

Article content

For more information see Note 4, Long-Term Debt in the Company’s Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026, and Note 5, Long-Term Debt in the Company’s Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2025.

Article content

Outstanding Share Data

Article content

As at June 30, 2026, the Company had 56,978,653 basic shares outstanding and 63,995,827 fully diluted shares outstanding.

Article content

Non-IFRS Financial and Other Measures

Article content

The Company discloses non-IFRS measures (such as EBITDA, Adjusted EBITDA, and gross margin) and non-IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company’s financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS.

Article content

EBITDA and Adjusted EBITDA

Article content

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines Adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, executive long-term performance and retention bonus, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction and other costs, impairment charges, gain on sale of building, finance income and loss or gain on sale of property, plant and equipment. Management believes EBITDA and Adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company’s ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes.

Article content

Article content

The following table provides a reconciliation of net and comprehensive income to EBITDA and Adjusted EBITDA:

Article content

Article content

Gross Margin and Gross Margin %

Article content

Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services (“COMS”). Gross margin % is calculated as gross margin divided by total revenue.

Article content

The following table provides a reconciliation of total revenue to gross margin:

Article content

Article content

For further details on the results, please refer to NeuPath’s Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026, which are available on the Company’s website ( www.neupath.com) and under the Company’s profile on SEDAR+ ( www.sedarplus.ca).

Article content

Notice of Investor Webinar

Article content

Event

Article content

: Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH)

Article content

Article content

Presentation Date & Time

Article content

: Thursday, August 13, 2026 at 11:00 AM ET / 8:00 AM PT

Article content

Article content

Webcast Registration Link:

Article content

Article content

About NeuPath

Article content

NeuPath operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain-related medical services. NeuPath provides improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. Working within Canada’s publicly funded healthcare system, NeuPath delivers insured medical services to help extend the appropriate care from hospitals into the community, which are complemented by select non-insured procedures to provide a comprehensive and coordinated treatment for patients. For additional information, please visit www.neupath.com.

Article content

Article content

Forward-Looking Statements

Article content

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation of continued operational improvements in 2026 and the execution of the Company’s growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s Annual Information Form dated March 25, 2026 filed on SEDAR

Article content

+

Article content

under the Company’s profile at

Article content

Article content

.

Article content

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

Article content

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content

For more information, please contact:

Article content

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

Article content